Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer's dementia

Street, J.; Clark, S.; Juliar, Beth E.; Feldman, Peter D.; Kadam, D.; Breier, Alan

doi:10.1016/s0924-977x(00)80486-1

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The beneficial effect of OL is well documented for psychosis in schizophrenic patients and in Alzheimer's disease patients (13). Its motor effects in hyperkinetic movement disorders have been reported in Tourette's syndrome patients (14) and two recent studies on chorea in HD (15, 16).…”

Section: Discussionmentioning

confidence: 99%

Olanzapine in Huntington's disease

Paleacu

Anca

Giladi

2002

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Olanzapine in Huntington's disease

Paleacu

Anca

Giladi

2002

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

show abstract

“…The long-term efficacy of olanzapine in this patient population was assessed in 137 patients who entered an open-label olanzapine (5, 10, or 15 mg/day) extension phase of up to 18 weeks (238). Following treatment with olanzapine, significant baseline to endpoint improvements were observed on the NPI/NH core total (P < 0.001), total (P < 0.001), and 10 of the 13 individual item scores of the NPI/NH, including Occupational Disruptiveness (P < 0.001).…”

Section: Olanzapine In Elderly Subjects and In Psychosis Associated Wmentioning

confidence: 99%

Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent

Tollefson

Taylor

2000

CNS Drug Reviews

View full text Add to dashboard Cite

The novel antipsychotic agent olanzapine (Zyprexa ® , Eli Lilly and Company) is a thienobenzodiazepine analog marketed for the treatment of schizophrenia. Olanzapine's diverse receptor binding profile and greater affinity for serotonin receptors over dopamine receptors is thought to impart antipsychotic efficacy with a low incidence of serious extrapyramidal symptoms (EPS). With once daily dosing steady-state plasma concentrations reached within approximately 1 week. Olanzapine is extensively metabolized by the liver, is mostly excreted in the urine, and has few drug intractions. In clinical trials, the efficacy of olanzapine for treating schizophrenia is better than placebo and haloperidol and comparable to risperidone. Olanzapine may also ameliorate some comorbid symptoms including negative symptoms, depression, anxiety, substance abuse, and cognitive dysfunction, and it is effective in the long-term maintenance of response, treatment-resistance, and improving quality of life. The overall direct costs are lower with olanzapine treatment compared with haloperidol or risperidone treatment. In clinical trials, olanzapine demonstrates a favorable safety profile. The most frequently reported treatment-emergent adverse events are somnolence, schizophrenic reaction, insomnia, headache, agitation, rhinitis, and weight gain. Significantly fewer EPS (based on formal rating scales) and incidences of tardive dyskinesia have been reported for olanzapine compared with haloperidol. Olanzapine has not been associated with persistent elevations of prolactin above the upper limit of normal nor has it been associated with clinically significant changes in cardiac QT c interval. Fewer incidences of suicide attempts have been reported with olanzapine compared with placebo, haloperidol, or risperidone treatments. There is evidence that olanzapine may be effective in the treatment of mood disorders, psychosis associated with 303

show abstract